No Data
On December 12, OCUMENSION-B (01477.HK) spent 0.086 million Hong Kong dollars to repurchase 0.018 million shares.
Gelonghui, December 12丨OCUMENSION-B (01477.HK) announced that on December 12, it spent 0.086 million HKD to repurchase 0.018 million shares.
Eucovision Bio-B (01477.HK) spent HKD 0.0526 million on December 9 to repurchase 0.0105 million shares.
On December 9, Gelonghui reported that Ocular Therapeutix Bio-B (01477.HK) announced it spent HKD 0.0526 million to repurchase 0.0105 million shares.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
On December 6, 2023, Eucan Vision Bio-B (01477.HK) spent 0.0204 million HKD to repurchase 4,000 shares.
Gelonghui, December 6th丨EOCNVIS Biotechnology-B (01477.HK) announced that on December 6th, it spent 0.0204 million Hong Kong dollars to buy back 4,000 shares.
Ocumension Therapeutics-B (01477.HK) bought back 4,000 shares on December 5th for 0.02 million Hong Kong dollars.
Gelonghui, December 5th丨EOCON Vision Biotechnology-B (01477.HK) announced that on December 5th, it spent 0.02 million HKD to repurchase 4,000 shares.
Companies Like Ocumension Therapeutics (HKG:1477) Are In A Position To Invest In Growth
No Data
